3 Reasons 2018 Will Be Better for NuVasive

NuVasive endured a fair amount of challenges in 2017, including significant management turnover and an ugly legal battle with competitor Alphatec. But three recent developments suggest this will be a better year for the San Diego-based spine company. 1. Extended Product Indications FDA recently expanded the 510(k) clearance for NuVasive's Coalesce thoracolumbar interbody fusion device and Cohere cervical interbody fusion device for multi-level cases from C2 to T1. NuVasive said the launch of Coalesce and the expanded indications of both these devices follow its September 2017 acquisition of Vertera Spine, a company that developed interbody implants for spinal fusion using porous polyetheretherketone (PEEK) technology. 2. Recent Acquisitions  NuVasive has made several tuck-in acquisitions recently that are expected to boost the company's 2018 revenue and earnings per share. This was one reason Needham & Company just upgraded NuVasive's stock to a "buy" rating from "underperform." Needham analyst Mike Matson noted in a report Thursday that NuVasive's acquisitions of Vertera and SafePassage could add about 2% to the company's 2018 revenue. NuVasive did not disclose the financial details of either deal. NuVasive announced its plans to acquire SafePassage in December. The deal is expected to strengthen the company's intraoperative neuromonitoring (IONM) business line, which was formed in July 2016 when NuVasive acquired Biotronic NeuroNetwork and combined its service...
Source: MDDI - Category: Medical Devices Authors: Tags: Orthopedics Medical Device Business Source Type: news